MedPath

A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

Phase 3
Completed
Conditions
Parkinson's Disease
Registration Number
NCT00134966
Lead Sponsor
Novartis
Brief Summary

The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level of 100 mg three times a day (t.i.d.).

Detailed Description

The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level 100 mg t.i.d.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
493
Inclusion Criteria
  • Aged 30 to 80 years, inclusive, at time of Parkinson's disease diagnosis
  • Idiopathic Parkinson's disease with at least 2 cardinal signs of disease: resting tremor, bradykinesia or rigidity
  • Parkinson's disease impairment warranting treatment with a levodopa formulation according to the investigator's assessment
Exclusion Criteria
  • History, signs or symptoms suggesting the diagnosis of atypical or secondary Parkinsonism due to drugs, metabolic disorders, encephalitis or other neurodegenerative diseases
  • History of stereotaxic brain surgery for PD (e.g., pallidotomy, deep brain stimulation, tissue transplant)
  • Diagnosis of Parkinson's disease for more than 5 years prior to Screening
  • Previous use of levodopa in any formulation, entacapone or tolcapone for more than 30 days or anytime within 4 weeks (28 days) prior to baseline
  • Use of a dopamine agonist within 4 weeks (28 days) prior to baseline

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Symptom control change from baseline to week 39
Secondary Outcome Measures
NameTimeMethod
Change from baseline to week 39 in incidence of dyskinesia and wearing off
Change from baseline to week 39 in mental acuity
Change from baseline to week 39 in activities of daily living
Change from baseline to week 39 in motor function

Trial Locations

Locations (59)

Dr. Felix Veloso Research

๐Ÿ‡จ๐Ÿ‡ฆ

Regina, Saskatchewan, Canada

Istituto Nazionale Neurologico "Carlo Besta"

๐Ÿ‡ฎ๐Ÿ‡น

Via Celoria 11, Milano, Italy

Dipartimento di Scienze Neurologiche Universitร  degli Studi di Roma "La Sapienza" Roma I

๐Ÿ‡ฎ๐Ÿ‡น

Viale dell'Universitร  30, Roma, Italy

Neurologicka klinika

๐Ÿ‡จ๐Ÿ‡ฟ

Katerinska 12, Praha 2, Czechia

FN-neurologickรก klinika

๐Ÿ‡จ๐Ÿ‡ฟ

Alej Svobody 80, Plzeลˆ, Czechia

FN-Nemocnice Pardubice

๐Ÿ‡จ๐Ÿ‡ฟ

Kyjevska 44, Pardubice, Czechia

Coastal Neurological Medical Group, Inc

๐Ÿ‡บ๐Ÿ‡ธ

La Jolla, California, United States

Barrow Neurology Clinics at St. Joseph's Hosptial & Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Phoenix, Arizona, United States

Neurosearch, Inc.

๐Ÿ‡บ๐Ÿ‡ธ

Reseda, California, United States

Mayo Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Jacksonville, Florida, United States

University of Florida Health Science Center

๐Ÿ‡บ๐Ÿ‡ธ

Jacksonville, Florida, United States

USF Medical Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Tampa, Florida, United States

Clinical Neuroscience Center

๐Ÿ‡บ๐Ÿ‡ธ

Southfield, Michigan, United States

Melbourne Internal Medicine Associates

๐Ÿ‡บ๐Ÿ‡ธ

Westlake, Ohio, United States

Springfield Neurology Associates, LLC

๐Ÿ‡บ๐Ÿ‡ธ

Springfield, Massachusetts, United States

NeuroHealth

๐Ÿ‡บ๐Ÿ‡ธ

Warwick, Rhode Island, United States

Westmoreland Neurology Associates, Inc.

๐Ÿ‡บ๐Ÿ‡ธ

Greensburg, Pennsylvania, United States

Lankenau Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Wynnewood, Pennsylvania, United States

Neurology Associates

๐Ÿ‡บ๐Ÿ‡ธ

San Marcos, Texas, United States

Baylor College of Medicine, Parkinson's Disease Center

๐Ÿ‡บ๐Ÿ‡ธ

Houston, Texas, United States

Heritage Medical Research Clinic

๐Ÿ‡จ๐Ÿ‡ฆ

Calgary, Alberta, Canada

Eastern Health Care - Health Sciences Centre, Neurology Department

๐Ÿ‡จ๐Ÿ‡ฆ

HSC Room 5317, 300 Prince Philip Drive, St. John's, Newfoundland and Labrador, Canada

Neurology Division, Health Science Center

๐Ÿ‡จ๐Ÿ‡ฆ

Halifax, Nova Scotia, Canada

Cape Breton Regional Hospital, Neurology Department

๐Ÿ‡จ๐Ÿ‡ฆ

Sydney, Nova Scotia, Canada

Grand River Hospital

๐Ÿ‡จ๐Ÿ‡ฆ

Kitchener, Ontario, Canada

London Health Sciences Center, University Hospital, Rm. A10-026

๐Ÿ‡จ๐Ÿ‡ฆ

London, Ontario, Canada

Centre for Movement Disorders

๐Ÿ‡จ๐Ÿ‡ฆ

Markham, Ontario, Canada

Ottawa Hospital, Civic Campus

๐Ÿ‡จ๐Ÿ‡ฆ

Ottawa, Ontario, Canada

Parkinson's & Neurodegenerative Disorders Clinic

๐Ÿ‡จ๐Ÿ‡ฆ

Ottawa, Ontario, Canada

Neuro Rive Sud

๐Ÿ‡จ๐Ÿ‡ฆ

Greenfield Park, Quebec, Canada

Montreal General Hospital

๐Ÿ‡จ๐Ÿ‡ฆ

Montreal, Quebec, Canada

Unite des Troubles du Mouvement Andre-Barbeau, CHUM-Hotel-Dieu

๐Ÿ‡จ๐Ÿ‡ฆ

Montreal, Quebec, Canada

Centre de Recjerche Clinique du CHUS

๐Ÿ‡จ๐Ÿ‡ฆ

Sherbrooke, Quebec, Canada

Neurologickรก klinika, Univerzita Palackรฉho

๐Ÿ‡จ๐Ÿ‡ฟ

I.P.Pavlova 6, Olomouc, Czechia

Quebec Memory and Motor Skills Disorders Clinic

๐Ÿ‡จ๐Ÿ‡ฆ

Quebec, Canada

University of Saskatchewan, Royal University Hospital

๐Ÿ‡จ๐Ÿ‡ฆ

Saskatoon, Canada

Rambam Medical Center

๐Ÿ‡ฎ๐Ÿ‡ฑ

Haliya Hashniya 8, Haifa, Israel

Dep. Of Neurology (Bitan 38, EEG institute)

๐Ÿ‡ฎ๐Ÿ‡ฑ

Dep. Of Neurology, Zerifin, Israel

Belinson Campus, Jabotinsky st. Movement Disorder Unit

๐Ÿ‡ฎ๐Ÿ‡ฑ

Petach Tikva, Israel

Sourasky Medical Center

๐Ÿ‡ฎ๐Ÿ‡ฑ

Weitzman St. Movement Disorder Clinic, Tel Aviv, Israel

Clinica Neurologica I - Azienda Ospedaliera-Universitaria Policlinico - Universitร  di Catania

๐Ÿ‡ฎ๐Ÿ‡น

Via Santa Sofia 78, Catania, Italy

Unitร  Operativa Complessa Neurologia - Policlinico Universitario "G. Martino"

๐Ÿ‡ฎ๐Ÿ‡น

Via Consolare Valeria, Messina, Italy

"Dipartimento di Neuroscienze Oftalmologia e Genetica (DINOG)

๐Ÿ‡ฎ๐Ÿ‡น

Universitร  degli Studi di Genova, Via De Toni 5, Genova, Italy

Dipartimento di Neuroscienze-Sezione Neurologia Universitร  degli Studi di Pisa- AO S. Chiara

๐Ÿ‡ฎ๐Ÿ‡น

Via Roma, 67, Pisa, Italy

Dipartimento di Neuroscienze-Universitร  degli Studi di Torino

๐Ÿ‡ฎ๐Ÿ‡น

Via Cherasco 15, Torino, Italy

A.O. Istituti Clinici di Perfezionamento-Unita'Operativa Centro Parkinson

๐Ÿ‡ฎ๐Ÿ‡น

Via Bignami 1, Milan, Italy

Samodzielny Publiczny Szpital Kliniczny Oddzial Kliniczny Neurologii i Epiletologii

๐Ÿ‡ต๐Ÿ‡ฑ

ul. Czerniakowska 231, Warszawa, Poland

Centrum Neurologii Klinicznej

๐Ÿ‡ต๐Ÿ‡ฑ

Ul. Dwernickiego 8, Krakow, Poland

Hospitais da Universidade de Coimbra (Serv. Neurologia)

๐Ÿ‡ต๐Ÿ‡น

Avenida Bissaya Barreto, Coimbra, Portugal

Klinika Neruologii Wieku Podeszlego

๐Ÿ‡ต๐Ÿ‡ฑ

ul.Medykow 14, Katowice, Poland

Hospital de Santa Maria (Serv. Neurologia)

๐Ÿ‡ต๐Ÿ‡น

Avenida Professor Egas Moniz, Lisbon, Portugal

Istanbul CAPA Medical School

๐Ÿ‡น๐Ÿ‡ท

Istanbul University CAPA Medical School, Dept. of Neurology, Istanbul, Turkey

Hacettepe Medical School, Department of Neurology

๐Ÿ‡น๐Ÿ‡ท

Hacettepe Universitesi Hastaneleri Norooji AD Sihhiye, Ankara, Turkey

Hospital de Santo Antรณnio (Serv. Neurologia)

๐Ÿ‡ต๐Ÿ‡น

Largo Professor Abel Salazar, Porto, Portugal

Dokuz Eylul Medical School, Department of Neurology

๐Ÿ‡น๐Ÿ‡ท

Noroloji Anabilim Dali Inciralti Izmir, Izmir, Turkey

Blue Ridge Research Center at Roanoke Neurological Center

๐Ÿ‡บ๐Ÿ‡ธ

Roanoke, Virginia, United States

Coastal Neurology, PA

๐Ÿ‡บ๐Ÿ‡ธ

Beaufort, South Carolina, United States

Senior Adults Specialty Research

๐Ÿ‡บ๐Ÿ‡ธ

Austin, Texas, United States

Hiren Desai Medicine Professional Corporation

๐Ÿ‡จ๐Ÿ‡ฆ

Windsor, Ontario, Canada

ยฉ Copyright 2025. All Rights Reserved by MedPath